Loading
A phase 2 trial of pembrolizumab in triple-negative breast cancer, run by Stephen Shiao, now recruiting.
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation is a phase 2, interventional study registered as NCT05491226 by Stephen Shiao, with a registry enrolment figure of 35 participants, started 2023-11-17 and due to reach its primary completion in 2026-12-01. Interventions recorded: Pembrolizumab; Radiation Therapy; Axatilimab. Conditions listed: TNBC - Triple-Negative Breast Cancer; Breast Cancer. Triple-negative eligibility wording from the registry: "* Female patients diagnosed with high-risk triple negative breast cancer (TNBC) with intent for neoadjuvant therapy". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.